Graybug Q3 net loss $9.8M; terminates GB-102/401 programs, cuts 20 of 28 staff

CalciMedica, Inc.

Net loss $9.8M in Q3 2022 vs $8.0M in Q3 2021; nine-month loss $28.2M vs $27.1M.
In August 2022, terminated 20 of 28 employees and wound down GB-102 (Phase 2b) and GB-401 programs; restructuring charge $2.4M.
R&D expense fell to $3.2M from $4.0M due to program halt; G&A rose to $4.3M from $4.0M on stock-based compensation.
Cash, equivalents, and short-term investments $43.6M; cash runway beyond 2023 subject to ongoing strategic review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CalciMedica, Inc. reported the nine months ended September 30, 2022 results: net income $28.2 million.

Period: the nine months ended September 30, 2022
Net income: $28.2 million
Result: reported results

Exact text from the filing

Net loss for the nine months ended September 30, 2022 was $28.2 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CalciMedica, Inc. reported the quarter ended September 30, 2022 results: net income $9.8 million.

Period: the quarter ended September 30, 2022
Net income: $9.8 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2022 was $9.8 million

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-282783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.